Pharmacovigilance – News and Features

Northwestern scientists developed a nanofiber therapy that halts toxic protein clumping in diseases like Alzheimer’s and ALS. These sugar-coated fibers trap misfolded proteins before they can damage neurons.

The clinical trial BROADWAY tested a once-daily oral medication called Obicetrapib, and found it significantly lowered both LDL cholesterol and lipoprotein(a), two key contributors to cardiovascular disease.

In research led by the Keck School of Medicine of USC, the new drug candidate selectively attacked glioblastoma stem cells and passed early safety testing in a phase 1 clinical trial.

In a real-world study of 234 Alzheimer’s patients, Washington University researchers found that lecanemab caused severe side effects in just 1%. Patients with very mild symptoms had the lowest risk and greatest benefit.

Researchers have employed a cross-species immunological analysis to provide new insights into a smallpox vaccine's immunogenicity and safety against the monkeypox virus.

The researchers have conducted a first-in-human clinical trial testing a CRISPR/Cas9 gene-editing technique aimed at enhancing the immune system’s ability to fight advanced gastrointestinal cancers.

A new study shows AI can design synthetic DNA to precisely control gene expression in healthy mammalian cells. The model created custom enhancers from scratch, enabling selective gene activation or suppression in blood cell types.

Scientists have developed eyedrops that can reverse inflammation and repair corneal stem cell damage in a mouse model of mustard keratopathy. The treatment may have broader potential for treating corneal injuries caused by burns or inflammation.

A next-generation “armored” CAR T cell therapy showed promising results in a small study of patients whose B-cell lymphomas continued to resist multiple rounds of other cancer treatments, including commercially available CAR T cell therapies.

In a first-of-its-kind study, treatment-resistant PTSD patients went symptom-free for at least six months after completing standard exposure therapy combined with vagus nerve stimulation.